Completed PHASE4 INTERVENTIONAL 2-arm NCT02106962

Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients

The Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients

Sponsor: California Institute of Renal Research

Interventions Topical Tranexamic Acid 25% with bacitracin Topical Tranexamic Acid 5% with bacitracin

Updated 8 times since 2017 Last updated: Aug 25, 2017 Started: Apr 30, 2014 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02106962, this PHASE4 trial focuses on Arteriovenous Fistula and remains completed. Sponsored by California Institute of Renal Research, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Oct 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jan 2017 — Oct 2017 [monthly]

Unknown Status PHASE4

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

California Institute of Renal Research
Imprimis Pharmaceuticals, Inc.

Data source: California Institute of Renal Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Diego, United States